To investigate whether chemical patterns in earwax could distinguish people with Ménière’s disease from those without it.
Approach:
Study design: A 2023 pilot study analyzed earwax from 15 people: seven without Ménière’s disease and eight with confirmed or tentative disease.
Methods: Researchers used direct analysis in real time-high-resolution mass spectrometry to profile samples and gas chromatography-mass spectrometry to identify and measure compounds.
Model testing: Statistical modeling used six samples from each group; the classification model was also tested on three additional samples.
Key Findings:
Three fatty acids—cis-9-hexadecenoic acid, cis-10-heptadecenoic acid, and cis-9-octadecenoic acid—were present in both groups but at lower concentrations in the Ménière’s disease group.
In targeted analysis, average concentrations were approximately 78%, 85%, and 58% lower, respectively, in the disease group.
The model categorized three additional samples correctly, but its internal classification performance was described as modest.
Interpretation:
The pilot findings indicate that earwax contains measurable biochemical patterns associated with Ménière’s disease, but they do not establish earwax analysis as a diagnostic test. The mass spectrometry-based technology remains at an early laboratory stage and has not been validated for clinical diagnosis.
Limitations:
The study included few participants, and testing on three additional samples is insufficient to establish diagnostic accuracy.
Larger prospective studies are needed to determine sensitivity and specificity and to compare Ménière’s disease with other vestibular disorders.
The effects of age, genetics, medication, diet, ear-cleaning practices, and sample collection on fatty acid levels remain to be assessed.
Conclusion:
The Research Foundation for the State University of New York announced that the test is available for licensing; a US patent application is pending.
